CALR mutation screening in pediatric primary myelofibrosis

Primary myelofibrosis (PMF) is quite rare in children. Mutations of JAK2V617F or MPLW515K/L were absent in pediatric patients with PMF according to previous studies. Recently, mutations in calreticulin (CALR) were described in adult patients with JAK2/MPL‐unmutated PMF. Our study aimed to analyze the clinical and genetic features of Chinese pediatric patients with PMF.

[1]  P. Guglielmelli,et al.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients , 2014, Leukemia.

[2]  A. Green,et al.  CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum , 2014, American journal of hematology.

[3]  D. Birnbaum,et al.  Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase , 2014, Haematologica.

[4]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[5]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[6]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[7]  M. Michalak,et al.  Calreticulin for better or for worse, in sickness and in health, until death do us part. , 2013, Cell calcium.

[8]  E. Kardami,et al.  Calreticulin Induces Dilated Cardiomyopathy , 2013, PloS one.

[9]  A. Tefferi,et al.  SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. , 2012, Blood.

[10]  J. Chandra,et al.  Chronic Childhood Idiopathic Myelofibrosis in Down’s Syndrome: A Case Report , 2012, Indian Journal of Hematology and Blood Transfusion.

[11]  M. Michalak,et al.  Calreticulin signaling in health and disease. , 2012, The international journal of biochemistry & cell biology.

[12]  A. Bertuch,et al.  Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis—An entity different from adults , 2012, American journal of hematology.

[13]  P. Guglielmelli,et al.  EZH2 mutational status predicts poor survival in myelofibrosis. , 2011, Blood.

[14]  M. McDevitt,et al.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes , 2011, Haematologica.

[15]  O. Abdel-Wahab,et al.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms , 2011, Leukemia.

[16]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Zitvogel,et al.  Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia , 2010, Cell Death and Disease.

[18]  D. Gilliland,et al.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[19]  D. Gilliland,et al.  IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis , 2010, Leukemia.

[20]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[21]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[22]  M. Michalak,et al.  ERp57 Modulates STAT3 Signaling from the Lumen of the Endoplasmic Reticulum* , 2009, The Journal of Biological Chemistry.

[23]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[24]  D. Birnbaum,et al.  Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.

[25]  H. Frangoul,et al.  Unrelated stem cell transplant for infantile idiopathic myelofibrosis , 2009, Pediatric blood & cancer.

[26]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[27]  S. Ellard,et al.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study , 2009, Haematologica.

[28]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[29]  A. Hall,et al.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.

[30]  P. Guglielmelli,et al.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. , 2008, The Journal of molecular diagnostics : JMD.

[31]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[32]  S. Collins,et al.  Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. , 2008, Cancer research.

[33]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[34]  T. Greiner.  Diagnostic Assays for theJAK2V617F Mutation in Chronic Myeloproliferative Disorders , 2006 .

[35]  T. Greiner.  Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2006, American journal of clinical pathology.

[36]  Monika Sharma,et al.  Idiopathic myelofibrosis with generalized periostitis in a 4-year-old girl. , 2005, Journal of pediatric hematology/oncology.

[37]  D. Head,et al.  Long‐term survival of infants with idiopathic myelofibrosis , 2000, British journal of haematology.

[38]  S. Grinstein,et al.  Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion , 1997, Nature.

[39]  U. Popat,et al.  Idiopathic myelofibrosis in children , 1996, British journal of haematology.

[40]  A. Mallouh,et al.  Agnogenic myeloid metaplasia in children. , 1992, American journal of diseases of children.

[41]  L. Boxer,et al.  Myelofibrosis-myeloid metaplasia in childhood. , 1975, Pediatrics.

[42]  Sanjeeva J. Wijeyesakere,et al.  Calreticulin in the immune system: ins and outs. , 2013, Trends in immunology.

[43]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.

[44]  Y. Rumpler,et al.  International Standing Committee on Human Cytogenetic Nomenclature , 1976 .